Xiangyu Deng

1 month ago | cell.com | Xiangyu Deng |Lina Sun |Min Zhang |Rashmi Basavaraj |Jin Wang |Yi-Lan Weng | +1 more

KeywordsRNA editingADAR1cryo-EMAicardi-Goutières syndromeGet full text accessLog in, subscribe or purchase for full access. References1. Nishikura, K. A-to-I editing of coding and non-coding RNAs by ADARsNat. Rev. Mol. Cell Biol. 2016; 17:83-962. Song, B. ∙ Shiromoto, Y. ∙ Minakuchi, M. ... The role of RNA editing enzyme ADAR1 in human diseaseWIREs RNA. 2022; 13, e16653. Quin, J. ∙ Sedmík, J. ∙ Vukić, D. ... ADAR RNA modifications, the epitranscriptome and innate immunityTrends Biochem. Sci. 2021; 46:758-7714.

1 month ago | biorxiv.org | Min Zhang |Xiangyu Deng |Yang Gao |Jin Wang

AbstractWang et al. in Nature Cancer report ZYS-1 as an ADAR1 inhibitor and present biochemical and cellular evidence to support ZYS-1's direct interaction with and inhibition of ADAR1, including enzymatic assays, surface plasmon resonance (SPR), drug affinity responsive target stability (DARTS), and cellular thermal shift assays (CETSA). We raise critical methodological concerns regarding the validation of ZYS-1 as a bona fide ADAR1 inhibitor.

Nov 23, 2023 | nature.com | Yi Ren |Xiangyu Deng |Yahui Zhan |Heng Li

AbstractCore genome multilocus sequence typing (cgMLST) is commonly used to classify bacterial strains into different types, for taxonomical and epidemiological applications. However, cgMLST schemes require central databases for the nomenclature of new alleles and sequence types, which must be synchronized worldwide and involve increasingly intensive calculation and storage demands.